We did not perform formal subgroup or sensitivity analyses by diabetes status, type of SGLT2 inhibitor, geographic region, or baseline patient characteristics, as stratified data were inconsistently reported across trials. The gene discussed is SLC5A2; the disease is diabetes mellitus.